Parmax Pharma's board has approved a preferential issue, allotting 31.37 lakh fully paid-up equity shares at Rs. 36.50 each to non-promoter investors, raising Rs. 11.45 Crore.

Additionally, 21.45 lakh convertible warrants were allotted at Rs. 36.50 each to non-promoter investors, convertible into equity shares within 18 months.

This capital raise strengthens the company's financial position and modifies the shareholding structure.

Importantly, several non-promoter allottees will transition into the promoter group upon allotment and warrant conversion, signaling a significant shift in ownership dynamics.